IBMX is a potent cyclic nucleotide phosphodiesterase inhibitor; due to this action, the compound increases cyclic AMP and cyclic GMP in tissue and thereby activates CYCLIC NUCLEOTIDE-REGULATED PROTEIN KINASES

簡要描述:IBMX 28822-58-4IBMX is a potent cyclic nucleotide phosphodiesterase inhibitor; due to this action, the compound increases cyclic AMP and cyclic GMP in tissue
產(chǎn)品分類
Product Category詳細(xì)介紹
| 品牌 | absin | CAS | 28822-58-4 |
|---|---|---|---|
| 分子式 | C10H14N4O2 | 純度 | 99% |
| 分子量 | 222.24 | 貨號 | abs47027840 |
| 規(guī)格 | 25mg | 供貨周期 | 現(xiàn)貨 |
| 主要用途 | is a potent cyclic nucleotide phosphodie | 應(yīng)用領(lǐng)域 | 化工,生物產(chǎn)業(yè),農(nóng)林牧漁,制藥/生物制藥,綜合 |
IBMX 28822-58-4
| 產(chǎn)品描述 | |
| 描述 | IBMX is a potent cyclic nucleotide phosphodiesterase inhibitor; due to this action, the compound increases cyclic AMP and cyclic GMP in tissue and thereby activates CYCLIC NUCLEOTIDE-REGULATED PROTEIN KINASES |
| 純度 | 99% |
| 儲存/保存方法 | Store at -20℃ for one year(Powder);Store at 2-4℃ for two weeks;Store at -20℃ for six months after dissolution. |
| 基本信息 | |
| 別名 | 3-異丁基-1-甲基黃piao呤; NSC165960;SC2964;IBMX;Isobutylmethylxanthine |
| 外觀 | Off-white powder |
| 可溶性/溶解性 | DMSO : 50 mg/mL (224.98 mM) Ethanol : ≥ 7.14 mg/mL (32.13 mM) |
| 生物活性 | |
| 靶點(diǎn) | Phosphodiesterase (PDE) |
| In vitro(體外研究) | At 100 μM, KMUP-1 (a xanthine derivative) and IBMX are the most effective at inducing tracheal relaxation; the magnitude of the relaxation responses induced by KMUP-1 and IBMX are not significantly different. IBMX (100 μM) activates renal outer medullary K+ (ROMK) channels (n=6, P+ (HK)-fed rats with IBMX (100 μM) for 20 min leads to a significant increase in tubular cAMP content to 1.43±0.35 pg/mm tubule length (n=14) compare with that measured in vehicle-treated controls (0.61±0.13 pg/mm tubule length, n=12, P. |
| In vivo(體內(nèi)研究) | IBMX, a non-selective PDE inhibitor significantly decreases the liver glycogen storage (mg/g, IBMX 22±1.5 P0.05) also mc2 does not change plasma glucose (control=141±3 and mc2=145±5). IBMX has the highest efficacy on increasing plasma glucose. Treatments with IBMX and Apocynin significantly decrease cold-induced elevation of right ventricular (RV) systolic pressure (23.5±1.8 and 24.2±0.6 mmHg, respectively) although they do not decrease RV pressure to the warm control levels. IBMX or Apocynin significantly reduces medial layer thickness (19.0±0.9, and 16.9±0.8 μm, respectively) and increases lumen diameter (62.7±4.2, and 59.5±4.3 μm, respectively) of small PAs in cold-exposed rats. |
| 研究領(lǐng)域 | |
| 研究領(lǐng)域 | Signal TransductionMetabolism Drug DiscoverySmall Molecule DrugLead Compound Discovery |
產(chǎn)品咨詢
